Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere. Sanofi-Aventis has said that both the companies have tried to copy their products. Earlier Sanofi-Aventis have filed separate complaints against Hospira Inc and Apotex Inc that they have violated the patent laws and have attempted to duplicate their top ranging product that is developed and marketed for the treatment of cancer patients. Though the market reacted sharply after the news broke into the market, but there was not much of fluctuation in the shares of Sanofi-Aventis at the end of the day.

Sanofi-Aventis is one of the leading pharmaceutical companies in France and globally as well. The company is into the research, development, manufacturing

...

PWRM, Power 3 Medical Products Inc, PWRM.OB

GVBP, GENova Biotherapeutics Inc, GVBP.OB

 

 

DrStockPick.com Stock Report!

 

Dr Stock Pick HOT News & Alerts!

Monday September 14, 2009

************************************************************** PWRM, Power 3 Medical Products Inc.

PWRM is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets.

PWRM and Transgenomic, Inc. announced recently the advance on-line publication of a clinical research paper entitled “Abnormal Serum Concentrations of Proteins in Parkinson’s Disease” in the scientific journal Biochemical and Biophysical Research Communications. The study demonstrates the usefulness of a protein biomarker

...

Amgen Inc. is a global biotechnology company engaged in the discovery, development, manufacture and commercialization of human therapeutics based on advances in cellular and molecular biology. The company has research programs in metabolic disorders and osteoporosis, inflammation, oncology, neuroscience and hematology.

Amgen is regarded to be the largest independent biotechnology company in the U.S. The company’s main products include: Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), which stimulate the production of red blood cells to treat anemia and belong to a class of drugs referred to as erythropoiesis stimulating agents (ESAs); Neulasta (pegflgrastim) and NEUPOGEN (Filgrastim), which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and ENBREL (etanercept) that blocks the biologic activity of tumor necrosis factor by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis.

The company’s research facilities

...

Based in San Diego, Amylin Pharmaceuticals Inc. (AMLN) is focused on the treatment of diabetes and other metabolic disorders. We have been cautious on Amylin since the beginning of the year, and we are still unconvinced that the sustained release formulation of Byetta, known as exenatide LAR, will be approved on its first cycle FDA review.However, with the shares trading at multi-year lows, and the stock down 70% YTD, the worst may be over for Amylin. Eli Lilly's (LLY) obvious commitment to Byetta and LAR will probably put a floor under further price declines. News that Lilly will move forward with the LAR filing in 2009 is a positive, but we are still unconvinced the drug will be approved on first cycle review due to lingering safety concerns.  In the meantime, an FDA decision on Byetta as a monotherapy could provide a boost ...